Immunologically active polypeptide
AssigneeInstitute of Arthritis Research, LLC
InventorCraig D. Scoville
Life of this patent
Estimating the term…
Abstract
Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.
Claims23
1-53. (canceled)
An isolated immunomodulatory polypeptide of no more than 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13 or 12 amino acids, which comprises either (i) the amino acid sequence KSIAYLQMNSLK as set forth in SEQ ID NO:2, or (ii) the amino acid sequence of general formula:
- K-X1-X2-X3-YLQM-X4-X5-LK as set forth in SEQ ID NO:106,
- wherein
- X1 is selected from S and N,
- X2 is selected from I, T, S, M, R and N,
- X3 is selected from A, L, V and Q,
- X4 is selected from N, D, S, T and A, and
- X5 is selected from S, T and N.
A method of treating a patient, comprising administering to the patient a therapeutically effective amount of an immunomodulatory polypeptide that comprises either the amino acid sequence set forth in SEQ ID NO:2 or the amino acid sequence set forth in SEQ ID NO:106, wherein the method is selected from:
- (a) a method of decreasing graft rejection wherein the patient is a transplant patient,
- (b) the method of (a) wherein the transplant is selected from kidney, heart, liver, pancreas and lung,
- (c) a method of treating or decreasing graft versus host disease wherein the patient is a bone marrow transplant patient,
- (d) a method of treating preeclampsia or hemolysis-elevated liver enzymes-low platelet count (HELLP) syndrome in the patient,
- (e) the method of (d) wherein the patient has been diagnosed with severe preeclampsia,
- (f) a method of treating rheumatoid arthritis in the patient,
- (g) a method of treating a malignant condition in the patient,
- (h) the method of (g) wherein treating the malignant condition comprises at least one of killing a tumor cell and inhibiting metastasis,
- (i) the method of (g) wherein the malignant condition is selected from breast cancer, ovarian cancer, adenoma, colorectal carcinoma, gastric carcinoma, lung carcinoma, prostate carcinoma, hepatocellular carcinoma, melanoma, leukemia and lymphoma,
- (j) a method of treating an autoimmune disease in the patient, and
- (k) the method of (j) wherein the autoimmune disease is selected from rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, seronegative spondyloarthopathies, systemic lupus erythematosus, Behcet's disease and vasculitis.
A method of inducing a peripheral blood white cell response that includes cellular release of at least one of IL-6, IL-10 and TNFα, comprising contacting one or a plurality of peripheral blood white cells in vitro or in vivo with an immunomodulatory polypeptide that comprises either the amino acid sequence set forth in SEQ ID NO:2 or the amino acid sequence set forth in SEQ ID NO:106, under conditions and for a time sufficient to induce detectable cellular release of at least one of IL-6, IL-10 and TNFα.
A method of treating an organ to be transplanted into an allogeneic recipient to reduce a likelihood or severity of allograft rejection by the recipient, comprising contacting the organ with an immunomodulatory polypeptide that comprises either the amino acid sequence set forth in SEQ ID NO:2 or the amino acid sequence set forth in SEQ ID NO:106, under conditions and for a time sufficient to reduce the likelihood or severity of allograft rejection.
A method of selectively labeling a mammalian peripheral blood white cell neutrophil subpopulation, comprising contacting a population of mammalian peripheral blood white cells which comprises neutrophils with an immunomodulatory polypeptide that comprises either the amino acid sequence set forth in SEQ ID NO:2 or the amino acid sequence set forth in SEQ ID NO:106, wherein the immunomodulatory polypeptide comprises a detectable label.
Dependencies are inferred from the claim text.